Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kathleen Corey, M.D.

Co-Author

This page shows the publications co-authored by Kathleen Corey and Tracey Simon.
Connection Strength

5.746
  1. Simon TG, Corey KE. Reply. Clin Gastroenterol Hepatol. 2020 02; 18(2):523-524.
    View in: PubMed
    Score: 0.902
  2. Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, Corey KE. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2776-2784.e4.
    View in: PubMed
    Score: 0.889
  3. Simon TG, Bamira DG, Chung RT, Weiner RB, Corey KE. Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity (Silver Spring). 2017 08; 25(8):1313-1316.
    View in: PubMed
    Score: 0.786
  4. Simon TG, Kartoun U, Zheng H, Chan AT, Chung RT, Shaw S, Corey KE. MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD). Hepatol Commun. 2017 Jul; 1(5):429-438.
    View in: PubMed
    Score: 0.776
  5. Kim MN, Lo CH, Corey KE, Liu PH, Ma W, Zhang X, Jovani M, Song M, Chan AT, Simon TG. Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women. Metabolism. 2020 12; 113:154398.
    View in: PubMed
    Score: 0.245
  6. Arvind A, Osganian SA, Sjoquist JA, Corey KE, Simon TG. Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis. Gastroenterology. 2020 Dec; 159(6):2232-2234.e4.
    View in: PubMed
    Score: 0.242
  7. Kaplan A, Simon TG, Henson JB, Wang T, Zheng H, Osganian SA, Rosenblatt R, Lake J, Corey KE. Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV. . 2020 Aug 01; 84(4):400-404.
    View in: PubMed
    Score: 0.242
  8. Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020 04; 51(7):728-736.
    View in: PubMed
    Score: 0.234
  9. Simon TG, Kim MN, Luo X, Yang W, Ma Y, Chong DQ, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Stampfer M, Zhang X, Giovannucci EL, Chan AT. Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. J Hepatol. 2020 Jun; 72(6):1062-1069.
    View in: PubMed
    Score: 0.233
  10. Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang X, Chan AT. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 2018 12 01; 4(12):1683-1690.
    View in: PubMed
    Score: 0.216
  11. Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, Chung RT, Giugliano RP. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018 Nov 01; 270:245-252.
    View in: PubMed
    Score: 0.208
  12. Simon TG, Trejo MEP, McClelland R, Bradley R, Blaha MJ, Zeb I, Corey KE, Budoff MJ, Chung RT. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018 05 15; 259:198-204.
    View in: PubMed
    Score: 0.208
  13. Simon TG, King LY, Chong DQ, Nguyen LH, Ma Y, VoPham T, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Khalili H, Chung RT, Zhang X, Chan AT. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology. 2018 05; 67(5):1797-1806.
    View in: PubMed
    Score: 0.206
  14. Simon TG, Corey KE, Chung RT, Giugliano R. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci. 2016 12; 61(12):3425-3435.
    View in: PubMed
    Score: 0.186
  15. Emdin CA, Haas M, Ajmera V, Simon TG, Homburger J, Neben C, Jiang L, Wei WQ, Feng Q, Zhou A, Denny J, Corey K, Loomba R, Kathiresan S, Khera AV. Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study. Gastroenterology. 2020 Dec 10.
    View in: PubMed
    Score: 0.062
  16. Meyersohn NM, Mayrhofer T, Corey KE, Bittner DO, Staziaki PV, Szilveszter B, Hallett T, Lu MT, Puchner SB, Simon TG, Foldyna B, Voora D, Ginsburg GS, Douglas PS, Hoffmann U, Ferencik M. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clin Gastroenterol Hepatol. 2020 Jul 21.
    View in: PubMed
    Score: 0.060
  17. Kartoun U, Corey KE, Simon TG, Zheng H, Aggarwal R, Ng K, Shaw SY. The MELD-Plus: A generalizable prediction risk score in cirrhosis. PLoS One. 2017; 12(10):e0186301.
    View in: PubMed
    Score: 0.050
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.